USL-311

DB15265InvestigationalSmall molecule

USL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)).

Formula / weight: C₂₄H₃₄N₆O · 422.577 g/mol (avg)
Also known as: 6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide
Code names: USL-311

Resolves to

Compound

UNII2BTG5MX2Q2CAS1373268-67-7ChEMBLCHEMBL4297449

Structure

InChIKeyXNUNVQKARNSSEO-UHFFFAOYSA-NSMILESCC(C)N1CCC(CC1)N1CCCN(CC1)C1=CC=CC(=N1)C(=O)NC1=CC=NC=C1

Targets

P61073CXCR4

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with USL-311, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account